Although immunosuppressed patients may be more prone to SARS‐CoV‐2 infection with atypical presentation, long‐term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID‐19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID‐19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID‐19 of a kidney‐transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.

中文翻译：

---

肾移植后从严重的 COVID-19 肺炎中成功康复：免疫抑制与包括托珠单抗在内的新疗法之间的相互作用。


尽管免疫抑制患者可能更容易出现非典型表现的 SARS-CoV-2 感染，但长期免疫抑制治疗可能为 COVID-19 的严重临床并发症提供某种保护。免疫抑制与新型抗病毒药物在治疗感染 COVID-19 的移植患者中的相互作用尚未得到充分研究。此外，有关这些患者最佳治疗的数据仍然非常有限。我们报告了一名接受羟氯喹、洛匹那韦/利托那韦、类固醇和托珠单抗治疗的肾移植患者从严重的 COVID-19 中成功康复的病例。